Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Healthcare

Paradigm (ASX:PAR) Reaches 50% Enrolment in Phase 3 Osteoarthritis Trial - Will Interim Analysis Be Its Defining Moment?

Paradigm Biopharmaceuticals is an Australian clinical-stage drug-development company focused on repurposing injectable pentosan polysulfate sodium (iPPS) for osteoarthritis and other conditions driven by inflammation. Osteoarthritis is a degenerative joint disease in which cartilage breaks down, causing pain and reduced mobility; knee osteoarthritis is among …

Ankur Sharma | 29 July 2026

Nova Eye (ASX:EYE) Lifts Guidance on Record US Glaucoma Sales

Nova Eye Medical is an Australian ophthalmic-device company focused on the surgical treatment of glaucoma, a group of eye conditions in which raised pressure inside the eye damages the optic nerve and can cause irreversible blindness. Its core technology supports canaloplasty, a minimally invasive …

Ankur Sharma | 29 July 2026

Syntara (ASX:SNT) Banks Parkinson's Milestone and Capital Raise

Syntara, formerly known as Pharmaxis, is an Australian drug-development company built around inhibitors of enzymes in the lysyl oxidase (LOX) family, which play a role in tissue scarring (fibrosis) and in certain cancers. Its lead asset, SNT-5505 (also called amsulostat, and previously PXS-5505), is …

Ankur Sharma | 29 July 2026

Imugene (ASX:IMU) Launches Capital Raise to Advance Azer-Cel CAR-T

Imugene is a clinical-stage immuno-oncology company developing therapies that harness the immune system to fight cancer. Its lead asset, azer-cel, is an allogeneic — or "off-the-shelf" — CAR-T therapy targeting CD19, a protein found on many B-cell blood cancers. CAR-T therapy involves engineering T …

Ankur Sharma | 29 July 2026

Neurizon (ASX:NUZ) Secures Funding for ALS Program Amid Leadership Refresh

Neurizon is an Australian drug-development company focused on neurodegenerative diseases, with ALS as its lead indication. ALS, also known as motor neurone disease, progressively destroys the nerve cells that control movement, and there are very few effective treatments. Neurizon’s lead candidate, NUZ-001 (monepantel), is …

Ankur Sharma | 29 July 2026

Medical Developments (ASX:MVP) Achieves Positive Cash Flow on Penthrox Growth

Medical Developments International is an Australian pharmaceutical and medical-device company best known for Penthrox, a handheld inhaler containing methoxyflurane that provides fast-acting relief from acute pain. Widely recognised in Australia as the "green whistle," Penthrox is used in emergency, trauma, ambulance and procedural settings, …

Ankur Sharma | 29 July 2026

Botanix (ASX:BOT) Raises Capital to Scale FDA-Approved Sofdra

Botanix Pharmaceuticals is a specialty pharmaceutical company whose lead product, Sofdra (sofpironium), is a topical gel approved by the US Food and Drug Administration for primary axillary hyperhidrosis — the medical term for excessive underarm sweating that is not caused by another condition. Botanix …

Ankur Sharma | 29 July 2026

Biome (ASX:BIO) Reports Record Revenue and Positive EBITDA

Biome Australia is a health company specialising in live microbiome and probiotic products — formulations containing beneficial bacteria intended to support digestive, immune and general health. Its flagship Activated Probiotics range is sold primarily through Australian community pharmacies and, increasingly, internationally. The company differentiates …

Ankur Sharma | 29 July 2026

Cyclopharm (ASX:CYC) Lands Major 11-Site US Technegas Agreement

Cyclopharm is an Australian nuclear-medicine company whose flagship product, Technegas, is used in functional lung imaging. Technegas is an inhaled aerosol of ultra-fine, technetium-99m-labelled carbon particles that a patient breathes in so that clinicians can image how air is distributed through the lungs — …

Ankur Sharma | 29 July 2026

Avecho (ASX:AVE) Phase 3 CBD Insomnia Trial Cleared to Continue

Avecho Biotechnology is an Australian drug-delivery and development company built around its proprietary TPM (tocopheryl phosphate mixture) technology, a delivery system derived from vitamin E that is designed to improve how poorly absorbed compounds are taken up by the body. Its lead clinical program …

Ankur Sharma | 29 July 2026
Support

Hi! How can we help you today?

Loading…